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Background/aim: Hyperparathyroidism is an endocrine disorder characterized by hypercalcemia. Because of calcium’s effects on
parathyroid glands, bone, intestines, and kidneys, it has an important place in homeostasis. The results of studies regarding
hyperparathyroidism hemostasis are conflicting. Thromboelastography helps to evaluate all steps of hemostatic system. Our aim in
this study was to investigate the possible role of hemostatic mechanisms in the development of thrombosis in hyperparathyroid
patients with the modified rotation thromboelastogram (ROTEM).
Materials and methods: Twenty-two patients with primary hyperparathyroidism (PHPT) and 20 healthy controls were involved.
This study was conducted in Eskisehir Osmangazi University Faculty of Medicine, Endocrinology and Hematology clinics for 2 years.
The complete blood count, fibrinogen, D-dimer levels, prothrombin time, activated prothrombin time, and ROTEM parameters [clot
formation time (CFT), clotting time (CT), and maximum clot formation (MCF)] were determined by two activated tests, INTEM and
EXTEM analyses. A thromboelastographic evaluation was performed in the preoperative and postoperative (3 months after surgery)
periods.
Results: In INTEM assay, the CT (p = 0.012) and CFT (p = 0.07) values were increased in preoperative PHPT patients compared with
the control group. Although there was a decrease in the postoperative CT and CFT values, no statistical difference was found.
Conclusion: The prolongation of the CT and CFT values were consistent with a hypocoagulable state in patients with PHPT.
Hyperparathyroidism causes a hypocoagulable state that can be successfully assessed by ROTEM. Hemostatic changes, do not seem to
have an effect on increased cardiovascular mortality.
Key words: Hyperparathyroidism, coagulation, thromboelastogram, ROTEM

1. Introduction
Calcium ion plays an important role in human physiology
such as cardiac automaticity, skeletal muscle and smooth
muscle contraction and relaxation, blood coagulation,
neuronal transmission, synaptic transmission, hormone
secretion, mitotic separation, cilial movement, bone
metabolism,
and
neurotransmitter
release.
Hypercalcemia is a metabolic disease with a clinical
spectrum ranging from asymptomatic biochemical
abnormalities
to
life-threatening
disorders.
Parathormone is the main regulator of extracellular
calcium
concentration
[1,2].
Primary
hyperparathyroidism (PHPT) increases calcium levels
and presents with abnormalities in both coagulation and
fibrinolysis. The literature contains studies about the
relationship
between
hyperparathyroidism
and
thrombosis, which reveal hypercoagulability and
hypofibrinogenemia [3–7]. In addition to high calcium
status, a tendency to coagulation is shown in secondary
*Correspondence: goknuryorulmaz@hotmail.com

hyperparathyroidism [8]. Studies evaluating coagulation
disorders in patients with primary hyperparathyroidism
are limited, and it has not yet been fully assessed whether
their effects on coagulation are due to hypercalcemia or
primary hyperparathyroidism. The results of a limited
number of studies do not always support each other [3–
8]. Hypercalcemia may cause thrombosis due to vascular
smooth muscle contraction and vasoconstriction or
platelet aggregation and coagulation factors. Additionally,
hypercalcemia may effect renal water and sodium
excretion resulting with dehydration. Considering all
these different mechanisms, the mechanism of
thrombosis in primary hyperparathyroidism is still
unclear [9–12].
Thromboelastography (TEG) is used to evaluate the
components of all steps in hemostasis [13]. Rotational
thromboelastogram (ROTEM), which developed from the
TEG technology, is superior to TEG even it has a good
correlation with the conventional method. It was possible
2897
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to evaluate heparin effect in differential diagnosis, platelet
and fibrinogen contribution in clot strengthening, and
diagnosis of hyperfibrinolysis with the addition of
activators or inhibitors in ROTEM, as a modified TEG
method. TEG has been used to explain various clinical
cases related to hypercoagulation such as postoperative
hypercoagulation and ischemic heart disease. Coagulation
disorders which cannot be detected in routine tests may
be noticed by ROTEM. ROTEM analysis has already placed
in diagnostic and treatment algorythms for patients with
bleeding. Also, ROTEM may be used to measure
hypercoagulopathy in several situations [13].
In this study, we aimed to investigate if the hemostatic
system plays a role in the development of thrombosis in
patients with PHPT. We evaluated coagulation status of
patients with PHPT to determine whether they could be
diagnosed based on the prolongation of clotting time (CT)
and clot formation time (CFT) values in both INTEM and
EXTEM assays. In this study, it was aimed to compare the
homeostatic system of PHPT cases with the preoperative
and postoperative control group, as TEG is a valuable tool
for clinicians to diagnose coagulopathy early.
2. Materials and methods
Twenty-two (20 females, two male) newly diagnosed
symptomatic PHPT patients (age: 55 ± 11 years) and 20
age-matched healthy normocalcemic female controls
(age: 49 ± 7 years) were included in this cohort study.
Patients that presented to the endocrinology outpatient
clinic for PHPT between January 2018-December 2019
were included in the study. The patients were evaluated
before and at the third month after parathyroidectomy.
Patients with known hematological or coagulation
diseases, using anticoagulant agents, and patients with
liver or renal failure were not included in this study.
The participants did not have any additional
cardiovascular risk factor. The diagnosis of PHPT was
based on high levels of albumin-corrected calcium, high
parathormone intact, and hypercalciuria. Before the
surgical procedure, preoperative imaging studies (neck
ultrasonography and dual-phase technetium-99m
sestamibi scintigraphy) were performed for localization.
The pathology results of all operated patients were
consistent with parathyroid adenomas. None of the
individuals were receiving any antiaggregant or
anticoagulant therapy. Samples were collected from all
patients to analyze the complete blood count (CBC),
prothrombin time (PT), activated prothrombin time
(aPTT), D-dimer, and TEG. Written informed consent was
obtained from all individuals participating in the study.
Control group was composed of voluntary individuals.
The study was approved by the local ethic committee of
the university.
2.1. Sample collection
Blood was collected from all participants under minimum
stasis from antecubital peripheric veins. Blood samples
were drawn into EDTA tubes (Becton Dickinson,
Plymouth, UK) for CBC and 4.5-mL vacutainers (Becton
2898

Dickinson, Plymouth, UK) containing 3.2% trisodium
citrate with a citrate/blood ratio of 1:9 for TEG and
coagulation profile. Both control group and patient group
samples were taken in morning fasting. CBC and
coagulation analyses were undertaken using an
automated hematology analyzer, ADVIA 2120i (Siemens,
New York, USA). Conventional coagulation parameters,
namely PT and aPTT, fibrinogen, and D-dimer were
obtained using an automatic coagulation analyzer
(BCS/XP, Siemens Healthcare Diagnostics, Malburg,
Germany). The normal ranges for these tests used in our
laboratory are 8.2– 13.2 s for PT, 24–40 s for aPTT, 200–
400 mg/dL for fibrinogen, and 0.00–0.50 mg/L for Ddimer. Thromboelastographic analyses were carried out
using the ROTEM Coagulation Analyzer (Pentapharm,
Munich, Germany). Three hundred μL of citrated whole
blood, which was recalcified with 20 μL 0.2mol/LCaCl2
(star-TEM; Pentapharm, Munich, Germany) was used for
each test. Intrinsic rotational thromboelastography
(INTEM) and extrinsic rotational thromboelastography
(EXTEM) tests were performed on each sample.
All the samples were analyzed within 30–90 min of
blood collection. CT, CFT, and MCF (maximal clot firming)
data were analysed to determine the pattern of clot
formation. CT measures the time from start of
measurement until initiation of clotting, CFT is the time
from initiation of clotting until a clot firmness of 20 mm is
detected and MCF describes the maximum amplitude,
indicative of the firmness of the clot.
2.2. Statistical analysis
Continuous data are given as mean ± standard deviation.
Categorical data are given as percentage (%). Shapiro–
Wilk’s test was used to investigate the compatibility of the
data for normal distribution. When comparing normally
distributed groups, independent sample t-test analysis
was used for cases with two groups. In comparison of
groups that do not conform to normal distribution, the
Mann–Whitney U test was used for cases where the
number of groups was two. In comparing the values at
different measurement times, Wilcoxon test was used
when the number of groups was two. IBM SPSS Statistics
21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for
Windows, v. 21.0. Armonk, NY: IBM Corp.) program was
used in the application of the analyzes. For statistical
significance, a value of p < 0.05 was accepted as the
criterion.
3. Results
Twenty-two (20 female, 2 male) newly diagnosed
symptomatic PHPT patients (age: 55 ± 11 years) and 20
age-matched healthy normocalcemic female controls
(age: 49 ± 7 years) were included in the study. The clinical
characteristics of the PHPT patients are summarized in
Table 1. The parathormone, alkaline phosphatase and
calcium levels were decreased postoperatively, as
expected. As expected, the parathormone, alkaline
phosphatase, and calcium levels improved in the
postoperative period (Table 1).
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Table 1. Clinical parameters of hyperparathyroid patients.
Preoperative (n = 22)
344  225.7
Parathormone (pg/mL)
229.1 (152.5–462.5)
19.94  16.01
Vitamin D
14.77 (10.3–23.00)
11.9  1.3
Calcium (mg/dL)
13.5 (12.73–14.65)
2.1  0.5
Phosphorus (mg/dL)
2.07 (1.82–2.55)
Alkaline phosphatase
144.3  87.9
(U/L)
155.6 (120.80–208.60)
13.48  1.55
Hemoglobin (mg/dL)
12.67 (11.96–14.09)
7.838  2.575
Leucocyte count (103/μL)
7.50 (6.50–8.50)
298.3  26.6
3
Platelet count (10 /μL)
231.50 (194.750–283.75)
92.1  9.5
Glucose (mg/dL)
91.00 (85.50–98.00 )
*SD: standard deviation, ¥ Paired sample t test, ¥¥ Wilcoxon test.
The values are presented as mean+/-SD and median (Q1-Q3).

Postoperative (n = 22)
43.69  14.5
43.85 (34.40–48.06)
22.98  10.11
24.5 (15.46–26.50)
9.2  0.37
9.28 (9.01–9.60)
3.5  0.4
3.38 (3.14–3.71)
94.1  47.3
103.30 (62.60–146.50)
13.17  2.05
12.80 (11.43–15.16)
7.048  3.476
6.50 (5.50–7.25)
252.1  68.6
243.50 (208.50–300.75)
91.1  9.3
90.00 (86.00–95.00)

P
0.001¥¥
0.216¥¥
<0.001¥
<0.001¥
0.006¥¥
0.130¥
0.204¥¥
0.454¥
0.527¥

Table 2. Comparison of the PT, aPTT, INR, PLT counts of the hyperparathyroid patients (preoperative measurements) and healthy
controls.
Postoperative (n =
Preoperative/Postoperative
Preoperative (n = 22)
Control (n = 20) P
22)
P
Pre-C:
Platelet count
298.3  26.6
252.1  68.6
224.2  40.2
<0.001¥¥
(103/μL)
231.50 (194.750 –
243.50 (208.50–
0.88¥
222.0 (186.00–
Post-C:
(mean ± SD)
283.75)
300.75)
285.00)
0.1204¥¥
Pre-C:
11.5  0.6
11.7  0.9
11.9  1
0.406¥¥
PT (sec.) *
0.28¥
11.50 (11.30–
11.50 (11.15 – 12.40) 11.80 (11.20–12.75)
Post-C:
11.85)
0.1286¥¥
Pre-C:
1.0  0.09
1.0  0.1
1.0  0.6
1.000¥¥
INR**
0.42¥
1.00 (0.90 – 1.07)
1.03 (1.00–1.05)
1.05 (0.67–1.46) Post-C:
1.000¥¥
Pre-C:
27.7  1.9
28.6  3.7
29.1  4.4
0.334¥¥
aPTT (sec.) ***
0.84¥
27.66 (26.56–
28.04 (26.00–31.25) 28.00 (26.25–29.25)
Post-C:
29.35)
0.1961¥¥
*PT, prothrombin time,**INR, international normalization ratio, APTT, activated partial thromboplastin time, *** ¥ Wilcoxon Test ¥¥
Mann–Whitney U test.
The values are presented as mean+/-SD and median (Q1-Q3). Preoperative vs. postoperative comparison was done with Wilcoxon
signed rank test and patients (either preoperative or postoperative) vs. control comparison was done with Mann–Whitney U test.

The PT, PTT, fibrinogen, and D-dimer levels did not
show any difference preoperatively and postoperatively
(Table 2). The correlation of the thromboelastogram
results with the PT, PTT, fibrinogen, and D-dimer levels of
the patients were not statistically significant. There was
no correlation between the EXTEM and INTEM
parameters and the platelet count, parathormone, Ddimer, calcium, and fibrinogen levels. The preoperative CT
and CFT were prolonged in the hyperparathyroid patients
according to the EXTEM and INTEM analyses (p < 0.05).
However, the MCF levels did not show any significant
difference preoperatively (Table 3). The preoperative and
postoperative CT, CFT, and MCF parameters of the

hyperparathyroid patients obtained from INTEM and
EXTEM did not show any significant difference (Table 4).
4. Discussion
The most important results of this research was that the
global clotting process was determined by ROTEM, and
the CT and CFT values were observed to be prolonged in
PHPT. TEG measures the viscoelastic properties of blood
and gives information about all steps of the coagulation
and fibrinolytic processes such as, plasma factors,
platelets, and leukocytes of all stages of the coagulation
and fibrinolytic processes [13]. The CT and CFT values of
the patients were still elevated at three months after the
2899
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Table 3. Comparison of the thromboelastometry parameters between the hyperparathyroid patients (preoperative measurements)
and healthy controls.
Patient group (preoperative) (n =22)
Control group (n = 20)
P¥
221.8  69.46
179.9  20.72
223.50 (187.75–260.00)
183.00 (169.00–190.00)
INTEM CFT**
145.0  107.15
87.85  16.78
117.50 (90.50–156.50)
84.00 (74.50–100.50)
INTEM MCF***
58.63  6.88
60.85  4.17
59.00 (55.75–62.25)
62.00 (58.50 – 63.50)
EXTEM CT
82.86  17.81
76.28  15.12
85.50 (77.75–94.00)
79.00 (71.00–82.50)
EXTEM CFT
144.04  64.36
99.85  23.17
133.50 (107.25–166.50)
94.00 (80.00–121.50)
EXTEM MCF
59.45  12.70
62.76  3.75
63.00 (58.75–65.25)
63.00 (61.00–66.00)
*CT: clotting time, ** CFT: clot formation time, ***MCF: maximal clot firmness, ¥ Mann–Whitney U test.
INTEM CT*

0.012
0.007
0.157
0.032
0.003
0.6

Table 4. Comparison of the preoperative and postoperative thromboelastometry parameters of the hyperparathyroid patients.
Preoperative measurement
Postoperative measurement
P¥
(n = 2)
(n: 22)
221.8  69.46
221.45  72.11
INTEM CT*
0.984
223.50 (187.75–260.00)
183.00 (169.00–190.00)
145.0  107.15
107.90  51.24
INTEM CFT**
0.181
117.50 (90.50–156.50)
84.00 (74.50–100.50)
58.63  6.88
61.20  5.44
INTEM MCF***
0.062
59.00 (55.75–62.25)
62.00 (58.50–63.50)
82.86  17.81
88.40  39.73
EXTEM CT
0.553
85.50 (77.75–94.00)
79.00 (71.00–82.50)
144.04  64.36
134.04  55.92
EXTEM CFT
0.596
133.50 (107.25–166.50)
94.00 (80.00–121.50)
59.45  12.70
65.4  6.96
EXTEM MCF
0.080
63.00 (58.75–65.25)
63.00 (61.00–66.00)
*CT: clotting time, ** CFT: clot formation time, ***MCF: maximal clot firmness ¥ Wilcoxon test.
The values are presented as mean+/-SD and median (Q1-Q3).

operation. CT and CFT are affected by the activities of
coagulation factors, and the prolongation of the CT and
CFT values in the present study confirmed the presence of
a hypocoagulable state. While other studies have shown a
tendency of patients toward a prothrombotic status [3], in
this study consistent with a hypocoagulable state is
obtained. In view of these findings, it is considered that the
increased cardiovascular mortality in patients with PHPT
may be associated with traditional cardiovascular risk
factors rather than hemostatic changes. Increased risk of
cardiovascular mortality in PHPT is known and does not
improve after parathyroidectomy [14–16]. The
prevalence of traditional cardiovascular risk factors is
increased in patients with PHPT [17]. Nevertheless, the
results about the effects of PHPT on the coagulationfibrinolytic system in the published data is conflicting.
Erem et al. evaluated the hemostatic system in PHPT and
showed an increase in some of the prothrombotic factors
[3,4]. In another study, Chertok-Shacham et al. reported a
positive relationship between the plasma PAI-1 antigen
and parathormone levels in 35 patients symptomatic
PHPT who do not have any evidence of cardiovascular
disease [18]. Boas et al. evaluated patients with chronic
kidney failure and secondary hyperparathyroidism
scheduled for total parathyroidectomy and reported that
they exhibited pro-thrombotic TEG parameters. In these
2900

studies, the researchers attempted to evaluate the
coagulation cascade with various factors in different
steps. The inconsistency may result from different
methods used to exclude the effect of concomittant
cardiovascular risk factors and also differences of serum
calcium levels. All studies concluded with a proposal of
studies with more patients, on the coagulation-fibrinolytic
function of patients with PHPT. There are ongoing studies
investigating the effect of serum calcium levels on platelet
aggregation, coagulation, and TEG parameters in healthy
people [8,19]. Recent study investigated the platelet
functions of patients with hyperparathyroidism using
platelet aggregation tests and determined that neither
primary and secondary hyperparathyroidism nor serum
calcium levels significantly affected platelet functions
[20]. Although Elbers et al. studied different groups of
hyperparathyroidism, they did not determine any effect of
hyperparathyroidism on coagulation or fibrinolysis [21].
In the current study, the MCF values, which are affected by
platelet count and function, did not show any significant
difference in the PHPT patients compared to the controls.
The difference in MCF was also nonsignificant between
the preoperative and postoperative measurements of the
patient group. The ROTEM-MCF data obtained from this
study confirm the idea that PHPT does not affect platelets.
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PHPT is the most common cause of postmenopausal
hypercalcemia. Studies show that the frequency of PHPT
had a F/M ratio of 3 to 4:1 [22–24]. The majority of our
patient group consisted of postmenopausal female
patients and we only had two male cases. Therefore, we
chose to form the control group with female patients. The
small number of patients, especially small number of male
patients is a limitation of this study. Another limitation of
the study is the lack of asymptomatic PHPT group.
In conclusion, hyperparathyroidism causes a
hypocoagulable state that can be successfully assessed by
ROTEM. Rather than hemostatic changes, cardiovascular
risk factors such as hypertension, glucose intolerance, and
dyslipidemia seem to be responsible for an increased risk
of cardiovascular mortality. Principally, contrary to
popular belief, since at least one group of PHPT patients
has an increased bleeding tendency, they should also be
followed up in this way in daily life and preoperatively.
However, further studies in greater series are needed to
elucidate the hemostatic system in patients with PHPT.
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